Related Experiment Videos
Apparent vitamin B6 deficiency in sickle cell anemia
The American Journal of Clinical Nutrition
|August 1, 1984
Summary
Pyridoxine supplementation may benefit sickle cell anemia patients. Studies show lower plasma pyridoxal phosphate (PLP) in patients, but higher erythrocyte PLP. Supplementation increased PLP levels and improved one patient's symptoms.
Area of Science:
- Biochemistry
- Hematology
- Nutritional Science
Background:
- Sickle cell anemia is characterized by abnormal hemoglobin.
- Pyridoxal phosphate (PLP) metabolism may be altered in sickle cell anemia.
Purpose of the Study:
- To investigate plasma and erythrocyte pyridoxal phosphate (PLP) levels in sickle cell anemia patients.
- To explore the potential therapeutic effects of pyridoxine supplementation in sickle cell anemia.
Main Methods:
- Measured plasma and erythrocyte PLP concentrations in 16 sickle cell anemia patients and 16 controls.
- Administered oral pyridoxine (50 mg twice daily for 2 months) to five patients.
- Monitored hematological parameters and clinical outcomes, including painful crises and hospitalizations.
Main Results:
- Plasma PLP was significantly lower, while erythrocyte PLP was significantly higher in sickle cell anemia patients compared to controls.
- Pyridoxine supplementation increased plasma and erythrocyte PLP levels.
- One patient experienced reduced painful crises and hospitalizations, with slight, non-significant improvements in erythrocyte count, Hb, and hematocrit.
Conclusions:
- Altered PLP distribution in sickle cell anemia suggests potential interactions with sickle hemoglobin.
- Pyridoxine supplementation shows promise as a therapeutic intervention for sickle cell anemia, warranting further investigation.
- In vivo therapeutic benefits of pyridoxine, including reduced disease severity, are suggested by preliminary findings.